Gilead expands access plans for investigational Ebola antiviral obeldesivir

Gilead Sciences has signed royalty-free voluntary licensing agreements with three generic drug manufacturers to support potential future access to investigational obeldesivir for post-exposure prophylaxis against Bundibugyo Ebola virus disease.

The agreements cover 127 primarily low- and lower-middle-income countries and are intended to establish manufacturing capacity, technology transfer and supply planning while clinical testing remains underway.

Dr. Reddy’s Laboratories, Eva Pharma and Ferozsons Laboratories have entered into the agreements with Gilead.

Technology transfer discussions are already underway, while Gilead said it is also discussing agreements with additional manufacturers.

Under the licences, the companies would be able to manufacture and supply obeldesivir across the covered territories if clinical data support its use and the treatment receives the necessary regulatory authorisations.

Obeldesivir is currently being evaluated in the Phase III EBO-PEP study as post-exposure prophylaxis for people at high risk of developing Bundibugyo Ebola virus disease.

The randomised, placebo-controlled field trial is being coordinated by ALIMA and its partners.

Gilead established the licensing agreements ahead of results from the study to support faster access if obeldesivir demonstrates clinical benefit.

The company is also expanding existing voluntary licences for remdesivir to cover filovirus disease.

The change is intended to support potential future access if results from the World Health Organization-sponsored PARTNERS study demonstrate that remdesivir is effective against Bundibugyo Ebola virus disease and regulatory approvals are subsequently obtained.

Neither obeldesivir nor remdesivir is currently approved for the treatment or prevention of Bundibugyo Ebola virus disease.

Obeldesivir has demonstrated preclinical activity against multiple filoviruses and has previously been evaluated in clinical studies for COVID-19 and respiratory syncytial virus.

Remdesivir has also demonstrated broad antiviral activity in laboratory and animal studies against pathogens including Ebola and Marburg viruses, as well as SARS-CoV-2.

However, Gilead said clinical efficacy of remdesivir against Bundibugyo Ebola virus disease has not yet been established.

Jaime McCoy, Vice President of Gilead Patient Solutions, said preparing manufacturing and supply arrangements before clinical results are available could reduce delays in delivering treatments during infectious disease outbreaks if they prove effective.

Gilead has also provided supplies of remdesivir for investigational use during the current outbreak.

More than 2,000 vials were recently donated to Kenya for use in people with confirmed Bundibugyo Ebola virus disease or those with close-contact exposure.

Across the Democratic Republic of the Congo, Uganda and Kenya, Gilead said it has provided more than 38,000 vials through compassionate-use donations during the outbreak response.

The voluntary licensing agreements form part of the company’s broader outbreak preparedness strategy, which includes clinical research, manufacturing planning, technology transfer and collaboration with governments and public health organisations.

Gilead said the aim is to establish supply mechanisms before regulatory decisions so that access can be expanded more rapidly if investigational treatments ultimately demonstrate benefit.



Related Topics and Keywords

, , , , , , , , , , , , , , , , , , , , , , , ,

Subscribe to our FREE newsletter and WEBINAR UPDATES

We will not sell or give your information to a third party. See our Privacy Policy